SEARCH

SEARCH BY CITATION

References

  • 1
    Sehgal SN, Baker H, Eng CP, Singh K, Vezina C. Demethoxyrapamycin (AY-24,668), a new antifungal antibiotic. J Antibiot 1983; 36:351354.
  • 2
    Calne RY, Collier DS, Lim S, Pollard SG, Samaan A, White AJ, Thiru S, et al. Rapamycin for immunosuppression in organ allografts. Lancet 1989; 2:227.
  • 3
    Morris RE, Wu J, Shorthouse R. A study of the contrasting effects of cyclosporine, FK 506, and rapamycin on the suppression of allograft rejection. Transplant Proc 1990; 22:16381641.
  • 4
    Murgia MG, Jordan S, Kahan BD. The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 1996; 49:209216.
  • 5
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: A phase II trial. Rapamune Study Group. Transplantation 1999; 68:15261532.
  • 6
    Watson CJ, Friend PJ, Jamieson NV, Frick TW, Alexander G, Gimson AE, Calne R, et al. Sirolimus: A potent new immunosuppressant for liver transplantation. Transplantation 1999; 67:505509.
  • 7
    McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355:376377.
  • 8
    Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockage of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31:335340.
  • 9
    Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144:251258.
  • 10
    Dumont FJ, Melino MR, Staruch MJ, Koprak SL, Fischer PA, Sigal NH. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 1990; 144:14181424.
  • 11
    Flanagan WM, Crabtree GR. Rapamycin inhibits p34cdc2 expression and arrests T lymphocyte proliferation at the G1/S transition. Ann N Y Acad Sci 1993; 696:3137.
  • 12
    Groth CG, Ohlman S, Gannedahl G, Ericzon BG. New immunosuppressive drugs in transplantation. Transplant Proc 1993; 25:26812683.
  • 13
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:10361042.
  • 14
    Thomson AW, Propper DJ, Woo J, Whiting PH, Milton JI, Macleod AM. Comparative effects of rapamycin, FK 506 and cyclosporine on antibody production, lymphocyte populations and immunoglobulin isotype switching in the rat. Immunopharmacol Immunotoxicol 1993; 15:355369.
  • 15
    Fruman DA, Burakoff SJ, Bierer BE. Immunophilins in protein folding and immunosuppression. FASEB J 1994; 8:391400.
  • 16
    Daly I, Ashok K, Jain B, Kashyap R, Fung JJ, Reyes J. Use of Mycophenolate Mofetil (MMF) for Chronic Rejection in Liver Allograft Under Tacrolimus. Berlin: ITLS; 2001.
  • 17
    Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP, et al. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999; 67:707712.
  • 18
    Hostetter TH. Chronic transplant rejection. Kidney Int 1994; 46:266279.
  • 19
    Weir MR, Anderson L, Fink JC, Gabregiorgish K, Schweitzer EJ, Hoehn-Sari C, et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64:17061710.